sodium stearyl fumorate | 4070-80-8

• 物质功能分类: 食品添加剂 - 面粉处理剂
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: sodium stearyl fumorate
• 英文别名: sodium stearyl fumarate；stearyl sodium fumarate；sodium;(E)-4-octadecoxy-4-oxobut-2-enoate
• CAS: 4070-80-8
• 化学式: C₂₂H₃₉O₄*Na
• 分子量: 390.539
• InChiKey: STFSJTPVIIDAQX-LTRPLHCISA-M

物化性质

• 熔点：
  >196°C (dec.)
• 溶解度：
  几乎不溶于水，微溶于甲醇，几乎不溶于丙酮和无水乙醇。
• LogP：
  8.789 (est)
• 稳定性/保质期：
  常温常压下稳定，为白色细粉。它溶于甲醇，几乎不溶于水。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  27
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/38
• WGK Germany：
  3
• 海关编码：
  2917190090
• 危险品运输编号：
  NONH for all modes of transport
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将药物存放在避光、通风干燥的地方，并密封保存。

SDS

Sodium Stearyl Fumarate Revision number: 5
SAFETY DATA SHEET

---

Section 1. IDENTIFICATION
Product name: Sodium Stearyl Fumarate

Revision number: 5

---

Section 2. HAZARDS IDENTIFICATION
GHS classification
PHYSICAL HAZARDS Not classified
Not classified
HEALTH HAZARDS
ENVIRONMENTAL HAZARDS Not classified
GHS label elements, including precautionary statements
Pictograms or hazard symbols None
No signal word
Signal word
Hazard statements None
None
Precautionary statements:

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance/mixture: Substance
Components: Sodium Stearyl Fumarate
Percent: >98.0%(T)
CAS Number: 4070-80-8
Synonyms: Fumaric Acid Stearyl Ester Sodium Salt , Sodium Octadecyl Fumarate , Fumaric Acid
Octadecyl Ester Sodium Salt
C22H39NaO4
Chemical Formula:

---

Section 4. FIRST AID MEASURES
Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Get medical advice/attention if you feel unwell.
Skin contact: Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower. If skin irritation or rash occurs: Get medical advice/attention.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. If eye irritation persists: Get medical
advice/attention.
Ingestion: Get medical advice/attention if you feel unwell. Rinse mouth.
A rescuer should wear personal protective equipment, such as rubber gloves and air-
Protection of first-aiders:
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing Dry chemical, foam, water spray, carbon dioxide.
media:
Sodium Stearyl Fumarate

---

Section 5. FIRE-FIGHTING MEASURES
Precautions for firefighters: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
Special protective When extinguishing fire, be sure to wear personal protective equipment.
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Use personal protective equipment. Keep people away from and upwind of spill/leak.
Personal precautions,
protective equipment and Entry to non-involved personnel should be controlled around the leakage area by
emergency procedures: roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
up: appropriate laws and regulations.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Handling is performed in a well ventilated place. Wear suitable protective equipment.
Technical measures:
Prevent dispersion of dust. Wash hands and face thoroughly after handling.
Use a local exhaust if dust or aerosol will be generated.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Conditions for safe storage, including any
incompatibilities
Storage conditions: Keep container tightly closed. Store in a cool and dark place.
Store away from incompatible materials such as oxidizing agents.
Packaging material: Comply with laws.

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Install a closed system or local exhaust as possible so that workers should not be
Engineering controls:
exposed directly. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Dust respirator. Follow local and national regulations.
Hand protection: Protective gloves.
Eye protection: Safety glasses. A face-shield, if the situation requires.
Skin and body protection: Protective clothing. Protective boots, if the situation requires.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Solid
Form: Crystal- Powder
Colour: White - Slightly pale yellow
Odour: No data available
pH: No data available
Melting point/freezing point:No data available
No data available
Boiling point/range:
Flash point: No data available
Flammability or explosive
limits:
No data available
Lower:
Upper: No data available
No data available
Relative density:
Solubility(ies):
No data available
[Water]
[Other solvents]
Hot acetic acid
Soluble:
Sodium Stearyl Fumarate

---

Section 10. STABILITY AND REACTIVITY
Chemical stability: Stable under proper conditions.
Possibility of hazardous No special reactivity has been reported.
reactions:
Incompatible materials: Oxidizing agents
Hazardous decomposition Carbon monoxide, Carbon dioxide
products:

---

Section 11. TOXICOLOGICAL INFORMATION
No data available
Acute Toxicity:
Skin corrosion/irritation: No data available
No data available
Serious eye
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
IARC = No data available
NTP = No data available
No data available
Reproductive toxicity:

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
No data available
Fish:
Crustacea: No data available
Algae: No data available
Persistence / degradability: No data available
Bioaccumulative No data available
potential(BCF):
Mobility in soil
Log Pow: No data available
No data available
Soil adsorption (Koc):
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
Observe all federal, state and local regulations when disposing of the substance.

---

Section 14. TRANSPORT INFORMATION
Hazards Class: Does not correspond to the classification standard of the United Nations
Not listed
UN-No:

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26, 2002
and revised on February 16,2011): Safe use and production, the storage of a dangerous chemical, transport,
loading and unloading were prescribed.
Sodium Stearyl Fumarate

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

硬脂富马酸钠是以硬脂醇与马来酸酐反应，将该产物同构化后加盐得到。这种润滑剂具有亲水性，在药物辅料中用作润滑剂，能解决因使用硬脂酸镁带来的问题，如主药受影响、过分润滑等；在泡腾片中可形成保护膜，改善崩解和溶出，从而提高生物利用度。

应用领域

硬脂富马酸钠（C22H39NaO4）是一种广泛应用且重要的药品与食品辅料。它大部分能被动物体代谢吸收，并水解产生硬脂醇和硬脂酸；小部分则可直接快速代谢。在药物领域，硬脂富马酸钠作为片剂和胶囊剂的润滑剂，同时可在泡腾片中形成保护膜，解决硬脂酸盐类润滑剂的问题，改善药物崩解与溶出，提高生物利用度。在食品工业中，FDA允许将其直接添加到供人食用的食物中，例如烘烤食品、面粉稠化食品、烘干马铃薯及处理过的谷物等，其最大添加量为0.2%至1.0%。

用途

硬脂富马酸钠用作片剂和胶囊剂的润滑剂，常用剂量为0.5%至2.0%，也用于某些食品中。它是一种亲水性润滑剂，在水中溶解度较低且受温度影响明显；用量稍大时泡腾溶液表面会出现白色漂浮物（硬脂富马酸钠），影响外观和口感。

作用

硬脂富马酸钠在药物制剂中可作为片剂和胶囊的润滑剂，还可形成泡腾片保护膜。它能解决硬脂酸盐类润滑剂带来的问题，改善药物崩解与溶出，提高生物利用度。此外，该辅料无刺激性，安全用于食品。

制备

一种硬脂富马酸钠辅料的制备方法包括以下步骤：首先，在80℃及以上温度下将马来酸酐、十八醇和反应溶剂混合进行开环反应；其次，加入转化剂进行转化反应；然后，降温至40-50℃后向体系中滴加含钠碱溶液搅拌反应，并在反应结束后降温析晶得到硬脂富马酸钠粗品。最后，对粗品进行精制处理以获得最终产品。

鉴别试验

通过薄层色谱法，在“硬脂酰马来酸钠和十八烷醇试验”中，试样液所得的大黄斑点比移值（R1）应与标准液A一致；用硫酸喷雾并加热后的主要色斑的Rf值也需与标准液B一致。

含量分析

准确称取约250mg样品放入50ml锥形瓶中，加入氯仿溶解后，再加冰醋酸和喹哪啶红试液，用0.1mol/L高氯酸的冰醋酸溶液滴定。每mL 0.1mol/L高氯酸相当于本品（C22H39NaO4）39.05mg。

毒性

硬脂富马酸钠可安全用于食品（FDA，§172.826，2000年版）。

使用限量

FDA规定：酵母发酵的焙烤制品，添加量为面粉量的0.5%；脱水马铃薯，添加量为1%；非酵母发酵焙烤制品用稳定剂，添加量为1%；谷类制品，添加量为1%；淀粉或小麦粉增稠剂，添加量为0.2%。

化学性质

硬脂富马酸钠是一种白色细粉，易溶于甲醇，几乎不溶于水。

用途

它作为面团调节剂、小麦粉处理剂和氧化剂。

反应信息

• 作为反应物：
  描述：

  sodium stearyl fumorate 生成 佐米曲普坦
  参考文献：
  名称：

  ORALLY DISINTEGRATING TABLETS OF ZOLMITRIPTAN AND PROCESS FOR PREPARING THE SAME

  摘要：

  硅酸二氧化物自由的口崩片制剂，含有重碳酸镁和富马酸钠十八酸酯的唑米曲普坦或其药学上可接受的盐，以及一种或多种药学上可接受的辅料，并提供制备这种制剂的方法，以及在治疗偏头痛中使用该制剂。

  公开号：

  US20110288138A1
• 作为产物：
  描述：

  monostearyl fumarate 在 sodium hydroxide 作用下， 以 水 、 丙酮 为溶剂， 反应 2.2h， 以181.36 g的产率得到sodium stearyl fumorate
  参考文献：
  名称：

  一种常用辅料的制备方法

  摘要：

  本发明涉及一种常用药物制剂辅料硬脂富马酸钠的制备方法，通过使用有机碱性催化剂，降低了反应温度，能够高收率地获得高质量的产物；通过对反应条件的选择，能够制备得到符合质量要求的产物，满足药物制剂的要求；本发明的方法操作简单，安全，成本低，适合工业化生产。

  公开号：

  CN104177260B
• 作为试剂：
  描述：

  一水氢溴酸右旋美沙芬 、 奎尼丁硫酸盐 在 N-乙烯基吡咯烷酮 、 甘露醇 、 DL-阿拉伯糖醇 、 silica gel 、 sucralose 、 sodium stearyl fumorate 作用下， 生成 dextromethorphan quinidine
  参考文献：
  名称：

  一种右美沙芬奎尼丁口崩片及其应用

  摘要：

  本发明提供一种右美沙芬奎尼丁口崩片、其制备方法和应用。该口崩片加入矫味剂以改善右美沙芬和奎尼丁味道极苦极麻的问题，且制得的口崩片易于崩解，解决了神经系统疾病患者吞咽困难问题的同时，大大改善了患者的用药体验。同时，本发明提供的右美沙芬奎尼丁口崩片制备工艺简单，适用于工业化大生产。

  公开号：

  CN114469882A

文献信息

• [EN] ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES<br/>[FR] FORMULATIONS ORALES DE DÉRIVÉS DE PYRROLIDINE
  申请人：OBSEVA SA

  公开号：WO2015091365A1

  公开（公告）日：2015-06-25

  The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one- O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.

  本发明涉及固体口服制剂，包括化合物的配方(3Z,5S)-5-(羟甲基)-1-[(2'-甲基-1,1'-联苯基-4-基)羰基]吡咯烷-3-酮-O-甲氧肟，和/或其活性代谢物，并且涉及所述制剂在治疗和/或预防早产、早产、经前痛经和子宫收缩引起的胚胎着床失败中的使用。本发明还涉及其制备方法。
• [EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DES PI3K
  申请人：ALMIRALL SA

  公开号：WO2014060432A1

  公开（公告）日：2014-04-24

  New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)

  新的吡咯三唑酮衍生物具有化学结构式（I），公开；以及它们的制备方法，包括它们的药物组合物和它们作为磷脂酰肌醇3-激酶（PI3Ks）抑制剂在治疗中的应用。
• Triazolone derivatives
  申请人：Clark Richard

  公开号：US20080015199A1

  公开（公告）日：2008-01-17

  A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R 1a , R 1b , R 1c and R 1d each independently represent hydrogen, etc.; R 2 represents optionally substituted phenyl, etc.; R 3 represents optionally substituted C6-10 aryl, etc.; and Z 1 and Z 2 each independently represent hydrogen]

  以下一般式（1）表示的化合物，其盐或上述化合物的水合物是一种新型化合物，可用于治疗和/或预防与血栓形成相关的疾病，并且具有适当的物理化学稳定性，更安全。 [其中R1a，R1b，R1c和R1d分别独立表示氢等；R2表示可选择取代的苯基等；R3表示可选择取代的C6-10芳基等；Z1和Z2分别独立表示氢]
• Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
  申请人：——

  公开号：US20030069170A1

  公开（公告）日：2003-04-10

  Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

  描述了包括药物-寡聚物共轭物、脂肪酸成分和胆盐成分的药物组合物。药物以共价键连接到寡聚物基团上。脂肪酸成分和胆盐成分以1:5至5:1的重量比存在。还提供了利用这种药物组合物治疗需要此类治疗的受试者的方法，以及提供这种药物组合物的方法。
• BROMODOMAIN INHIBITORS FOR TREATING DISEASE
  申请人：Board of Regents, The University of Texas System

  公开号：US20160060260A1

  公开（公告）日：2016-03-03

  Disclosed herein are compounds and compositions useful in the treatment of bromodomain-containing protein-mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibiting activity of a bromodomain-containing protein in a human or animal subject are also provided.

  本文披露了一种在治疗溴结构域含蛋白介导的疾病（如癌症）中有用的化合物和组合物，其具有Formula I的结构： 还提供了一种抑制人类或动物主体中溴结构域含蛋白活性的方法。